Kymera Therapeutics NASDAQ:KYMR reported that Chief Operating Officer Jeremy G. Chadwick sold company stock totaling $9,048,290 in transactions executed on March 23 and March 25. The sales covered 95,077 shares at per-share prices ranging from $76.7329 to $80.2586.
Concurrently, Chadwick exercised stock options to acquire 109,127 shares of Kymera stock at an exercise price of $29.64 per share, representing a total option exercise value of $3,234,524. The insider activity was carried out under a pre-arranged Rule 10b5-1 trading plan that the company says was adopted on December 10, 2025.
Following the completion of these transactions, Chadwick directly holds 61,202 shares of Kymera Therapeutics. The filings disclose both the option exercises and the open-market sales occurring on the cited March dates.
Market context provided in the reporting notes Kymera's share price at $78.91 at the time of the disclosure. The stock has gained 134% over the past year but was still 23% below its 52-week high of $103. An InvestingPro analysis referenced in the disclosure indicates the stock currently appears overvalued relative to its Fair Value, and points readers toward the Pro Research Report available for Kymera and more than 1,400 U.S. equities.
Operationally, Kymera has a pipeline update in the calendar: data from the KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented at the American Academy of Dermatology 2026 Annual Meeting. The company described this forthcoming presentation as part of its continuing research efforts in skin conditions.
Analysts have recently adjusted their outlooks and price targets for Kymera following the company's fourth-quarter and full-year 2025 results. Stephens raised its price target to $100 and kept an Overweight rating. Morgan Stanley lowered its target to $123 but maintained an Overweight rating, citing progress in Kymera’s degrader pipeline and market opportunities in type 2 diseases. RBC Capital raised its price target to $108, maintained an Outperform rating, and noted the potential for a quieter year as phase II development for KT-621 continues.
These corporate and analyst developments form the backdrop to the insider transactions. The filings indicate the sales and option exercises were implemented according to the already established 10b5-1 plan, a detail the company disclosed in its reporting of the trades.
Investors and observers tracking insider activity, clinical milestones for KT-621, and the divergence of analyst price targets will likely weigh these items alongside the company's latest public disclosures and market valuation commentary provided by InvestingPro.